Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL2273341

C(=N/c1ccccc1)\c1ccccc1.N

nearest known ligand 0.61

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.61
CA2 P00918 5/20 0.61
L3MBTL1 Q9Y468 5/20 0.61
CA1 P00915 4/20 0.61
KDM4E B2RXH2 4/20 0.61
GLA P06280 1/20 0.61
PTGS2 P35354 2/20 0.57
CA9 Q16790 2/20 0.57
PTGS1 P23219 1/20 0.57
CA12 O43570 1/20 0.57
LMNA P02545 3/20 0.55
S100B P04271 1/20 0.48
MAOA P21397 1/20 0.48
MAPT P10636 5/20 0.45
MEN1 O00255 4/20 0.45
KMT2A Q03164 4/20 0.45
THRB P10828 3/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
MAPK1 P28482 2/20 0.45
TP53 P04637 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL60000 0.97 ALDH1A1 (0.63) ALDH1A1CA2L3MBTL1CA1KDM4E
SCHEMBL13084384 0.97 ALDH1A1 (0.63) ALDH1A1CA2L3MBTL1CA1KDM4E
SCHEMBL59999 0.97 ALDH1A1 (0.63) ALDH1A1CA2L3MBTL1CA1KDM4E
SCHEMBL9685935 0.95 ALDH1A1 (0.61) ALDH1A1CA2L3MBTL1CA1KDM4E
SCHEMBL1374708 0.95 ALDH1A1 (0.61) ALDH1A1CA2L3MBTL1CA1KDM4E
Water SCHEMBL15846002 0.95 ALDH1A1 (0.61) ALDH1A1CA2L3MBTL1CA1KDM4E
SCHEMBL28312209 0.95 ALDH1A1 (0.61) ALDH1A1CA2L3MBTL1CA1KDM4E
SCHEMBL340770 0.95 ALDH1A1 (0.61) ALDH1A1CA2L3MBTL1CA1KDM4E
SCHEMBL22577661 0.95 ALDH1A1 (0.61) ALDH1A1CA2L3MBTL1CA1KDM4E
Fluoride SCHEMBL28271051 0.95 ALDH1A1 (0.61) ALDH1A1CA2L3MBTL1CA1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108069939-B Compound containing conjugated dienamide structure, preparation method, pharmaceutical composition and application thereof 中国科学院上海药物研究所 2020-03-10 CN disclosed
CN-108069939-A Compound, its preparation method, pharmaceutical composition and purposes containing conjugation connection acrylamide structure 中国科学院上海药物研究所 2018-05-25 CN disclosed
US-20150238485-A1 OXIME-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AS ORL-1 MODULATORS SHIONOGI & CO., LTD. (JP) 2015-08-27 US disclosed
US-9040533-B2 Oxime-substituted-quinoxaline-type piperidine compounds as ORL-1 modulators PURDUE PHARMA L.P. (US) 2015-05-26 US disclosed
WO-2014102592-A2 OXIME/SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF PURDUE PHARMA L.P. (US) 2014-07-03 WO disclosed
US-20140187544-A1 OXIME-SUBSTITUTED-QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF SHIONOGI & CO., LTD. (JP) 2014-07-03 US disclosed
EP-1836212-B1 MACROLIDE COMPOUNDS CONTAINING BIOTIN AND PHOTO-AFFINITY GROUP FOR MACROLIDE TARGET IDENTIFICATION GLAXO GROUP LTD (GB) 2011-09-07 EP disclosed
US-7989600-B2 Bioconjugation; drug screening GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. 2011-08-02 US disclosed
US-20080241959-A1 Macrolide Compounds Containing Biotin and Photo-Affinity Group for Macrolide Target Identification GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) 2008-10-02 US disclosed
EP-1836212-A1 MACROLIDE COMPOUNDS CONTAINING BIOTIN AND PHOTO-AFFINITY GROUP FOR MACROLIDE TARGET IDENTIFICATION GlaxoSmithKline istrazivacki centar Zagreb d.o.o. (HR) 2007-09-26 EP disclosed
WO-2006106440-A1 MACROLIDE COMPOUNDS CONTAINING BIOTIN AND PHOTO-AFFINITY GROUP FOR MACROLIDE TARGET IDENTIFICATION GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (US) 2006-10-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080241959-A1 Macrolide Compounds Containing Biotin and Photo-Affinity Group for Macrolide Target Identification BTD, HLCS, MRPL12 ALDH1A1 4489/4885CA2 4790/4885L3MBTL1 1387/4885
US-20150238485-A1 OXIME-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AS ORL-1 MODULATORS OPRL1, OGFRL1, OPRD1 ALDH1A1 110/4885CA2 731/4885L3MBTL1 279/4885
US-20140187544-A1 OXIME-SUBSTITUTED-QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF QSOX1, OPRK1, OPRD1 ALDH1A1 221/4885CA2 631/4885L3MBTL1 1254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.